Published in Bioconjug Chem on February 03, 2010
Folate-targeted nanoparticles show efficacy in the treatment of inflammatory arthritis. Arthritis Rheum (2011) 1.03
Polyvalent dendrimer-methotrexate as a folate receptor-targeted cancer therapeutic. Mol Pharm (2012) 0.92
Polyvalent saccharide-functionalized generation 3 poly(amidoamine) dendrimer-methotrexate conjugate as a potential anticancer agent. Bioorg Med Chem (2011) 0.82
Design and in vitro validation of multivalent dendrimer methotrexates as a folate-targeting anticancer therapeutic. Curr Pharm Des (2013) 0.80
Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol (2007) 17.80
Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res (2005) 4.71
Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res (1992) 3.66
The binding avidity of a nanoparticle-based multivalent targeted drug delivery platform. Chem Biol (2007) 3.36
Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc Chem Res (2007) 3.03
Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev (2000) 2.85
Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discov Today (2001) 2.71
Differential regulation of folate receptor isoforms in normal and malignant tissues in vivo and in established cell lines. Physiologic and clinical implications. Cancer (1994) 2.58
Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev (2004) 2.56
Folate receptor-mediated drug targeting: from therapeutics to diagnostics. J Pharm Sci (2005) 2.46
Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers. Proc Natl Acad Sci U S A (1996) 2.39
Poly(amidoamine) dendrimer-based multifunctional engineered nanodevice for cancer therapy. J Med Chem (2005) 2.32
Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm Res (2002) 2.30
PAMAM dendrimer-based multifunctional conjugate for cancer therapy: synthesis, characterization, and functionality. Biomacromolecules (2006) 2.17
Folate-binding protein is a marker for ovarian cancer. Cancer Res (1991) 2.12
Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim Biophys Acta (1995) 1.92
Targeting and inhibition of cell growth by an engineered dendritic nanodevice. J Med Chem (2005) 1.80
Dendritic polymer macromolecular carriers for drug delivery. Curr Opin Chem Biol (2002) 1.77
Macromolecular MRI contrast agents with small dendrimers: pharmacokinetic differences between sizes and cores. Bioconjug Chem (2003) 1.67
Studies of the role of a particulate folate-binding protein in the uptake of 5-methyltetrahydrofolate by cultured human KB cells. J Biol Chem (1985) 1.50
Cellular localization of the folate receptor: potential role in drug toxicity and folate homeostasis. Cancer Res (1992) 1.38
Amphiphilic multi-arm-block copolymer conjugated with doxorubicin via pH-sensitive hydrazone bond for tumor-targeted drug delivery. Biomaterials (2009) 1.27
The use of PAMAM dendrimers in the efficient transfer of genetic material into cells. Pharm Sci Technolo Today (2000) 1.23
Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. Proc Natl Acad Sci U S A (1995) 1.21
HPLC analysis of PAMAM dendrimer based multifunctional devices. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 1.07
Antitumoral activity of PEG-gemcitabine prodrugs targeted by folic acid. J Control Release (2008) 1.02
HPLC separation of different generations of poly(amidoamine) dendrimers modified with various terminal groups. Anal Chem (2005) 0.96
HPLC analysis of functionalized poly(amidoamine) dendrimers and the interaction between a folate-dendrimer conjugate and folate binding protein. Analyst (2006) 0.92
Selective targeting of malignant cells with cytotoxin-folate conjugates. J Drug Target (1994) 0.84
Bispecific agents target endogenous murine T cells against human tumor xenografts. Int J Cancer (1999) 0.80
Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res (2005) 4.71
The binding avidity of a nanoparticle-based multivalent targeted drug delivery platform. Chem Biol (2007) 3.36
Interaction of polycationic polymers with supported lipid bilayers and cells: nanoscale hole formation and enhanced membrane permeability. Bioconjug Chem (2006) 2.87
Interaction of poly(amidoamine) dendrimers with supported lipid bilayers and cells: hole formation and the relation to transport. Bioconjug Chem (2004) 2.66
Nanoparticle interaction with biological membranes: does nanotechnology present a Janus face? Acc Chem Res (2007) 2.34
Poly(amidoamine) dendrimer-based multifunctional engineered nanodevice for cancer therapy. J Med Chem (2005) 2.32
Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm Res (2002) 2.30
PAMAM dendrimer-based multifunctional conjugate for cancer therapy: synthesis, characterization, and functionality. Biomacromolecules (2006) 2.17
Synthesis and functional evaluation of DNA-assembled polyamidoamine dendrimer clusters for cancer cell-specific targeting. Chem Biol (2005) 2.05
Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex. Adv Drug Deliv Rev (2005) 1.97
Wide varieties of cationic nanoparticles induce defects in supported lipid bilayers. Nano Lett (2008) 1.96
Protein modification, bioconjugation, and disulfide bridging using bromomaleimides. J Am Chem Soc (2010) 1.89
Targeting and inhibition of cell growth by an engineered dendritic nanodevice. J Med Chem (2005) 1.80
Dendritic polymer macromolecular carriers for drug delivery. Curr Opin Chem Biol (2002) 1.77
Applications of nanotechnology for immunology. Nat Rev Immunol (2013) 1.65
Tumor angiogenic vasculature targeting with PAMAM dendrimer-RGD conjugates. Chem Commun (Camb) (2005) 1.58
Lipid bilayer disruption by polycationic polymers: the roles of size and chemical functional group. Langmuir (2005) 1.56
Dendrimer-entrapped gold nanoparticles as a platform for cancer-cell targeting and imaging. Small (2007) 1.45
Direct observation of lipid bilayer disruption by poly(amidoamine) dendrimers. Chem Phys Lipids (2004) 1.42
Bromomaleimides: new reagents for the selective and reversible modification of cysteine. Chem Commun (Camb) (2009) 1.40
Tunable reagents for multi-functional bioconjugation: reversible or permanent chemical modification of proteins and peptides by control of maleimide hydrolysis. Chem Commun (Camb) (2011) 1.38
Pre-event smallpox vaccination and postevent exposure and disease: a report of the Joint Task Force on Smallpox Vaccination for Allergists. Ann Allergy Asthma Immunol (2005) 1.38
HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb. Bioconjug Chem (2006) 1.36
In situ maleimide bridging of disulfides and a new approach to protein PEGylation. Bioconjug Chem (2011) 1.33
Dendrimer-epidermal growth factor conjugate displays superagonist activity. Biomacromolecules (2008) 1.31
A quantitative assessment of nanoparticle-ligand distributions: implications for targeted drug and imaging delivery in dendrimer conjugates. ACS Nano (2010) 1.29
Targeted gadolinium-loaded dendrimer nanoparticles for tumor-specific magnetic resonance contrast enhancement. Int J Nanomedicine (2008) 1.28
Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge. Infect Immun (2007) 1.27
Cationic nanoparticles induce nanoscale disruption in living cell plasma membranes. J Phys Chem B (2009) 1.27
Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy. Bioconjug Chem (2004) 1.24
Synthesis, characterization, and in vitro testing of superparamagnetic iron oxide nanoparticles targeted using folic Acid-conjugated dendrimers. ACS Nano (2008) 1.22
The role of apoptosis in thyroid autoimmunity. Thyroid (2007) 1.20
Pre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccine. PLoS One (2008) 1.20
Synthesis, characterization, and intracellular uptake of carboxyl-terminated poly(amidoamine) dendrimer-stabilized iron oxide nanoparticles. Phys Chem Chem Phys (2007) 1.20
Game-based exercises for dynamic short-sitting balance rehabilitation of people with chronic spinal cord and traumatic brain injuries. Phys Ther (2007) 1.18
Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates. AIDS Res Hum Retroviruses (2008) 1.18
Development of immune response that protects mice from viral pneumonitis after a single intranasal immunization with influenza A virus and nanoemulsion. Vaccine (2003) 1.17
Real-time biomolecular binding detection using a sensitive photonic crystal biosensor. Anal Chem (2010) 1.17
Task-specific rehabilitation of finger-hand function using interactive computer gaming. Arch Phys Med Rehabil (2008) 1.16
Bromopyridazinedione-mediated protein and peptide bioconjugation. Chem Commun (Camb) (2011) 1.15
Sensitive molecular binding assay using a photonic crystal structure in total internal reflection. Opt Express (2008) 1.14
Current dendrimer applications in cancer diagnosis and therapy. Curr Top Med Chem (2008) 1.14
Silver/dendrimer nanocomposites as biomarkers: fabrication, characterization, in vitro toxicity, and intracellular detection. Nano Lett (2005) 1.13
In vitro targeting of synthesized antibody-conjugated dendrimer nanoparticles. Biomacromolecules (2004) 1.13
Two-photon fluorescence correlation spectroscopy through a dual-clad optical fiber. Opt Express (2008) 1.12
Isolation and characterization of dendrimers with precise numbers of functional groups. Chemistry (2010) 1.11
Poly(amidoamine) dendrimers on lipid bilayers II: Effects of bilayer phase and dendrimer termination. J Phys Chem B (2008) 1.10
Bromomaleimide-linked bioconjugates are cleavable in mammalian cells. Chembiochem (2011) 1.09
HPLC analysis of PAMAM dendrimer based multifunctional devices. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 1.07
Induction of Th17 cellular immunity with a novel nanoemulsion adjuvant. Crit Rev Immunol (2010) 1.07
Synthetic PAMAM-RGD conjugates target and bind to odontoblast-like MDPC 23 cells and the predentin in tooth organ cultures. Bioconjug Chem (2007) 1.06
The role of ganglioside GM1 in cellular internalization mechanisms of poly(amidoamine) dendrimers. Bioconjug Chem (2009) 1.05
Light-controlled release of caged doxorubicin from folate receptor-targeting PAMAM dendrimer nanoconjugate. Chem Commun (Camb) (2010) 1.04
A novel, killed-virus nasal vaccinia virus vaccine. Clin Vaccine Immunol (2007) 1.03
Dendrimer-based targeted delivery of an apoptotic sensor in cancer cells. Biomacromolecules (2007) 1.03
Cationic poly(amidoamine) dendrimer induces lysosomal apoptotic pathway at therapeutically relevant concentrations. Biomacromolecules (2009) 1.03
Folate-targeted nanoparticles show efficacy in the treatment of inflammatory arthritis. Arthritis Rheum (2011) 1.03
Poly(amidoamine) dendrimers on lipid bilayers I: Free energy and conformation of binding. J Phys Chem B (2008) 1.02
Effects of an interactive computer game exercise regimen on balance impairment in frail community-dwelling older adults: a randomized controlled trial. Phys Ther (2011) 1.02
In Vivo Monitoring of Multiple Circulating Cell Populations Using Two-photon Flow Cytometry. Opt Commun (2008) 1.02
A novel inactivated intranasal respiratory syncytial virus vaccine promotes viral clearance without Th2 associated vaccine-enhanced disease. PLoS One (2011) 1.02
Quantitative two-photon flow cytometry--in vitro and in vivo. J Biomed Opt (2008) 1.01
Quantitative analysis of generation and branch defects in G5 poly(amidoamine) dendrimer. Polymer (Guildf) (2013) 1.00
The implications of stochastic synthesis for the conjugation of functional groups to nanoparticles. Bioconjug Chem (2008) 1.00
Understanding specific and nonspecific toxicities: a requirement for the development of dendrimer-based pharmaceuticals. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2010) 1.00
Homogeneous antibody fragment conjugation by disulfide bridging introduces 'spinostics'. Sci Rep (2013) 0.99
Best practices for purification and characterization of PAMAM dendrimer. Macromolecules (2012) 0.98
Efficacy, immunogenicity and stability of a novel intranasal nanoemulsion-adjuvanted influenza vaccine in a murine model. Hum Vaccin (2010) 0.98
The fungicidal activity of novel nanoemulsion (X8W60PC) against clinically important yeast and filamentous fungi. Mycopathologia (2002) 0.98
Polymeric dibromomaleimides as extremely efficient disulfide bridging bioconjugation and pegylation agents. J Am Chem Soc (2012) 0.98
Molecular dynamics studies of the size, shape, and internal structure of 0% and 90% acetylated fifth-generation polyamidoamine dendrimers in water and methanol. J Phys Chem B (2006) 0.97
Preclinical antitumor efficacy evaluation of dendrimer-based methotrexate conjugates. Anticancer Drugs (2008) 0.97
Multifunctional dendrimer-modified multiwalled carbon nanotubes: synthesis, characterization, and in vitro cancer cell targeting and imaging. Biomacromolecules (2009) 0.97
HPLC separation of different generations of poly(amidoamine) dendrimers modified with various terminal groups. Anal Chem (2005) 0.96
A unique combination of inflammatory cytokines enhances apoptosis of thyroid follicular cells and transforms nondestructive to destructive thyroiditis in experimental autoimmune thyroiditis. J Immunol (2002) 0.96
IFNgamma sensitization to TRAIL-induced apoptosis in human thyroid carcinoma cells by upregulating Bak expression. Oncogene (2004) 0.95
Design of riboflavin-presenting PAMAM dendrimers as a new nanoplatform for cancer-targeted delivery. Bioorg Med Chem Lett (2010) 0.94
HER2 specific delivery of methotrexate by dendrimer conjugated anti-HER2 mAb. Nanotechnology (2008) 0.94